1 of 25

Best Practices for Substance Use Screening and Treatment in the Emergency Department

SEMINAL STUDY

9.5

9.4 // Mental Health & Substance Use

9.6 // Opioid Use Disorder Treatment in the ED

9 BEHAVIORAL HEALTH

2 of 25

Disclosures

No relevant disclosures or conflicts of interest to disclose

3 of 25

Learning objectives

  1. Identify evidence-based screening and referral practices for substance use disorders and implement effective screening, brief intervention, and treatment (SBIRT) programs based in the ED
  2. Develop a harm-reduction framework for assisting patients with substance use disorders in the ED

4 of 25

Epidemiology and costs

Nearly half of all emergency department (ED) visits in the US are related to substance use disorders (SUD)

More than 20 million Americas ages 12 and older have an SUD yet only a minority receive addiction treatment

SUD-related costs related to productivity, healthcare, and crime exceed 400 billion dollars per year

Despite increasing rates of ED visits for SUD and fatal overdoses during the COVID pandemic, evidence-based treatments remain under-utilized

5 of 25

Screening questions for substance use disorders

The ED visit is an opportunity to screen for SUD, initiate behavioral and pharmacological interventions, and link patients to longitudinal treatment

Validated ED-appropriate screening tools are available for alcohol (AUDIT-C, the CAGE questionnaire, NIAAA single-question screen) and SUD (e.g., DAST, NIDA)—including tobacco

6 of 25

Screening questions for substance use disorders

NIAAA (alcohol): “How many times in the past year have you had 5 [men] or 4 [women, elderly] or more drinks in a day?

NIDA Quick Screen Single drug use question: “How many times in the past year have you used an illegal drug or used a prescription medication for nonmedical reasons? (100% sensitive, 74% specific for drug use disorder (DUD) in primary care settings)

7 of 25

Screening questions for substance use disorders

8 of 25

Motivational interviewing

ED visits are “teachable moments” to reduce complications from SUD

Brief ED interventions based on motivational interviewing (MI) in may facilitate behavioral change through a 4-step process—engaging, focusing, evoking, planning

MI based on empathetic, nonjudgmental open questions, reflective listening, and summarizing

Studies in ED settings show mixed results, likely from heterogeneous methods and populations

9 of 25

Interventions for alcohol: gauging risk

Spectrum of alcohol use:

  • At-risk: exceeds NIAAA recommendations
  • Harmful: causes mental/physical damage
  • Hazardous: increases risk of harm
  • Alcohol use disorder (AUD): meets >/= 2 DSM-V criteria

10 of 25

Interventions for alcohol

Goals: reduce frequency/quantity, prevent injury (e.g., driving), engage in AUD treatment (improved with direct transfer to treatment facility)

Brief ED interventions show reductions in injuries, return ED visits (moderate quality evidence)

MI-based intervention (e.g., Brief Negotiated Interview) may decrease frequency and consumption

Systematic review of ED interventions showed 41% reduced odds of alcohol-related injury at 6 and 12 months

Screening, brief intervention, and referral to treatment (SBIRT) for alcohol may reduce healthcare costs

11 of 25

Interventions for opioid and illicit drug use

Evidence for SBIRT for DUD more limited than AUD

Brief interventions show decreases in overdose risk behaviors and non-medical opioid use, and increased treatment engagement

Brief intervention for opioid use disorder (OUD) and ED-initiated buprenorphine associated with decreased opioid use and cost-effectiveness

12 of 25

Interventions for tobacco

Evidence for ED-initiated interventions weak to moderate quality

May increase tobacco abstinence at 1 month

Higher abstinence rates when combining brief intervention, nicotine replacement therapy, and quitline referral

13 of 25

ED pharmacological interventions for substance use disorders

  • ED initiation of medications for OUD (buprenorphine/methadone) with linkage to treatment
  • Referral for buprenorphine/methadone/naltrexone therapy for OUD
  • Gabapentin and naltrexone for AUD
  • Mirtazapine for problematic methamphetamine use
  • Bupropion and naltrexone for methamphetamine use disorder
  • Nicotine replacement therapy for tobacco use disorder

14 of 25

Peer recovery coaching

Peers in addiction treatment trained in MI may facilitate transitions to longitudinal care and sustain engagement

One observational study demonstrated shorter time to new OUD medication start when ED patients got a peer recovery coach, though overall uptake was slower

A 2022 RCT showed no difference in treatment engagement at 30 days between peer-led and social work interventions for ED patients with recent opioid overdose

15 of 25

Treatment referral for substance use disorders

Linkage to SUD treatment after discharge is facilitated by designated ED clinical champions and formal protocol for warm handoff to community providers

Best practices for treatment linkage include automated EHR-embedded processes, multiple referral options, and encrypted referral messaging (EHR, email, fax)

16 of 25

Harm reduction principles

Harm reduction: strategies and practices by and for people who use drugs to reduce their risks (e.g., overdose, HIV, HCV, skin infections)

Given the prevalence of fentanyl and its analogs in the unregulated drug supply, opioid overdose risk is not restricted to people with OUD

17 of 25

Harm reduction interventions

  • Fentanyl test strips
  • Safer use kits for injection, smoking, and snorting (e.g., alcohol preps, sterile syringes/needles, pipes, straws*)
  • Referral to syringe service programs (SSPs)
  • Take-home naloxone
  • Education (e.g., don’t use alone, start low and go slow)

*May be limited by local/state paraphernalia laws

18 of 25

Assessment questions

All of the following are evidence-based pharmacological treatments for substance use disorders except

  1. Naltrexone for alcohol use disorder
  2. Naltrexone for methamphetamine use disorder
  3. Gabapentin for alcohol use disorder
  4. Gabapentin for methamphetamine use disorder

19 of 25

Assessment questions

All of the following are evidence-based pharmacological treatments for substance use disorders except

  1. Naltrexone for alcohol use disorder
  2. Naltrexone for methamphetamine use disorder
  3. Gabapentin for alcohol use disorder
  4. Gabapentin for methamphetamine use disorder

20 of 25

Assessment questions

All of the following are associated with reduced harm from risky substance use except

  1. ED take-home naloxone for patients who use stimulants
  2. Court-appointed abstinence-based programs for opioid use disorder
  3. Referral to syringe service programs for patients who inject opioids
  4. Copper mesh to prevent hot particle inhalation when smoking methamphetamine

21 of 25

Assessment questions

All of the following are associated with reduced harm from risky substance use except

  1. ED take-home naloxone for patients who use stimulants
  2. Court-appointed abstinence-based programs for opioid use disorder
  3. Referral to syringe service programs for patients who inject opioids
  4. Copper mesh to prevent hot particle inhalation when smoking methamphetamine

22 of 25

References

Hawk, K., & D'Onofrio, G. (2018). Emergency department screening and interventions for substance use disorders. Addict Sci Clin Pract, 13(1), 18.

Chua, K. P., Dahlem, C. H. Y., Nguyen, T. D., Brummett, C. M., Conti, R. M., Bohnert, A. S., Dora-Laskey, A. D., & Kocher, K. E. (2022). Naloxone and Buprenorphine Prescribing Following US Emergency Department Visits for Suspected Opioid Overdose: August 2019 to April 2021. Ann Emerg Med, 79(3), 225-236. https://doi.org/10.1016/j.annemergmed.2021.10.005

Barata, I. A., Shandro, J. R., Montgomery, M., Polansky, R., Sachs, C. J., Duber, H. C., Weaver, L. M., Heins, A., Owen, H. S., Josephson, E. B., & Macias-Konstantopoulos, W. (2017). Effectiveness of SBIRT for Alcohol Use Disorders in the Emergency Department: A Systematic Review. West J Emerg Med, 18(6), 1143-1152. https://doi.org/10.5811/westjem.2017.7.34373

CA Bridge (2023). Resources. Retrieved May 3, 2023 from https://cabridge.org/tools/resources/

Herring, A. A., & Kaleekal, J. (2022). Bridge for Meth: Multi-Center Prospective Evaluation of Emergency Department Initiation of Mirtazapine for Problematic Methamphetamine Use [ABSTRACT]. Ann Emerg Med, 80(4). https://doi.org/https://doi.org/10.1016/j.annemergmed.2022.08.052

23 of 25

References

Trivedi, M. H., Walker, R., Ling, W., Dela Cruz, A., Sharma, G., Carmody, T., Ghitza, U. E., Wahle, A., Kim, M., Shores-Wilson, K., Sparenborg, S., Coffin, P., Schmitz, J., Wiest, K., Bart, G.,

Sonne, S. C., Wakhlu, S., Rush, A. J., Nunes, E. V., & Shoptaw, S. (2021). Bupropion and Naltrexone in Methamphetamine Use Disorder. N Engl J Med, 384(2), 140-153.

https://doi.org/10.1056/NEJMoa2020214

Samuels, E. A., Bernstein, S. L., Marshall, B. D. L., Krieger, M., Baird, J., & Mello, M. J. (2018). Peer navigation and take-home naloxone for opioid overdose emergency department patients: Preliminary patient outcomes. J Subst Abuse Treat, 94, 29-34. https://doi.org/10.1016/j.jsat.2018.07.013

Beaudoin, F. L., Jacka, B. P., Li, Y., Samuels, E. A., Hallowell, B. D., Peachey, A. M., Newman, R. A., Daly, M. M., Langdon, K. J., & Marshall, B. D. L. (2022). Effect of a Peer-Led Behavioral

Intervention for Emergency Department Patients at High Risk of Fatal Opioid Overdose: A Randomized Clinical Trial. JAMA Netw Open, 5(8), e2225582.

https://doi.org/10.1001/jamanetworkopen.2022.25582

24 of 25

References

Patel, E., Solomon, K., Saleem, H., Saloner, B., Pugh, T., Hulsey, E., & Leontsini, E. (2022). Implementation of buprenorphine initiation and warm handoff protocols in emergency departments: A qualitative study of Pennsylvania hospitals. J Subst Abuse Treat, 136, 108658. https://doi.org/10.1016/j.jsat.2021.108658

Ahmed, O. M., Mao, J. A., Holt, S. R., Hawk, K., D'Onofrio, G., Martel, S., & Melnick, E. R. (2019). A scalable, automated warm handoff from the emergency department to community sites offering continued medication for opioid use disorder: Lessons learned from the EMBED trial stakeholders. J Subst Abuse Treat, 102, 47-52. https://doi.org/10.1016/j.jsat.2019.05.006

25 of 25

SEMINAL STUDY

Opioid Use Disorder Treatment in the EMERGENCY DEPARTMENT

9.6

10.1 // Understanding Disparities in Rural Health

10.2 // Rural EM Clinical Practice

Up next: